• Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

Asthma Research Update: 7 Studies At-a-Glance for Primary Care

Article

Recent studies have reported the latest developments in asthma research. Scroll through these slides to find concise summaries of key points for clinical practice.

Recent studies have reported the latest developments in asthma research. Scroll through the slides below to find concise summaries of key points for clinical practice.

slideshow image
Related Videos
Tezepelumab Reduces Asthma Exacerbations by More than Half, Reports NAVIGATOR Study Author
Tezepelumab Reduces Asthma Exacerbations by More than Half, Reports NAVIGATOR Study Author
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Asthma of Obesity: Investigator Explains the Phenotypes
Asthma of Obesity: Investigator Explains the Phenotypes
Asthma Guidelines in Practice: Clinicians Rate their Adherence
Asthma Guidelines in Practice: Clinicians Rate their Adherence
Expert Interview: The Challenge of Asthma Management in Primary Care
Expert Interview: The Challenge of Asthma Management in Primary Care
Related Content
FDA Accepts Depemokimab BLA for Asthma and Chronic Rhinosinusitis with Nasal Polyps

FDA Accepts Depemokimab BLA for Asthma and Chronic Rhinosinusitis with Nasal Polyps

Patient Care Editorial Staff
March 6th 2025
Article

The FDA set the Prescription Drug User Fee Act (PDUFA) date for December 16, 2025.

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

Sydney Jennings
May 20th 2022
Podcast

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

Postnatal Antibiotics for Maternal Indications May Heighten Childhood Asthma Risk / Image credit: ©DragonImages/AdobeStock

Postnatal Antibiotics for Maternal Indications May Heighten Childhood Asthma Risk

Sydney Jennings
February 12th 2025
Article

AAAAI 2025. Early postnatal antibiotic exposure in full-term infants was associated with a 30% increased risk of childhood asthma, according to a new study.

Site Logo

Eternal Springs

Faith T. Fitzgerald, MD
January 13th 2010
Podcast

Doctors, especially primary care doctors, love stories. We love hearing them from patients and telling them to one another. “Anecdotal learning” it’s called by some (somewhat derisively because it’s not science).

Albuterol/Budesonide Reduces Risk of Exacerbation in People with Intermittent, Mild-Persistent Asthma

Albuterol/Budesonide Reduces Risk of Exacerbation in People with Intermittent, Mild-Persistent Asthma

Grace Halsey
October 7th 2024
Article

Albuterol/budesonide (Airsupra) has now proven effective as novel combination as-needed rescue medication for adults with asthma regardless of disease severity.

States with Higher COVID-19 Vaccination Rates Saw Reduction in Pediatric Asthma Prevalence / Image credit: ©Alessandro Grandini/AdobeStock

States with Higher COVID-19 Vaccination Rates Saw Reduction in Pediatric Asthma Prevalence

Sydney Jennings
July 9th 2024
Article

A new study shows that higher vaccination rates were associated with a decrease in the prevalence of parent-reported asthma symptoms in children.

© 2025 MJH Life Sciences

All rights reserved.